Become a QuantumOnline Supporter!

Quick Search
    Hint: For Preferreds Try XXX-D
    Hint: For Securites No Longer Traded, Try XXX* or XXX-D*
    Hint: For All Securites of XXX, Search XXX, and click Find All Related Securities link.
    Top Banner


    Register for QuantumOnline.com


    Fortress Biotech, 9.375% Series A Cumulative Perpetual Preferred Shares
    Ticker Symbol: FBIOP     CUSIP: 34960Q208     Exchange: NCM
    Security Type:   Traditional Preferred Stock

    Security's Distribution is Suspended!

    QUANTUMONLINE.COM SECURITY DESCRIPTION:  Fortress Biotech, Inc., 9.375% Series A Cumulative Redeemable Perpetual Preferred Shares, liquidation preference $25 per share, redeemable at the issuer's option on or after 12/15/2022 at $25 per share plus accrued and unpaid dividends, and with no stated maturity.

    Cumulative distributions of 9.375% per annum ($2.34375 per annum or $0.58594 per quarter) will be paid quarterly on 3/31, 6/30, 9/30 & 12/31 to holders of record on the record date that will be 3/15, 6/15, 9/15 & 12/15 Amended on 06/17/2020 to a 0.1953125 dividend paid monlthy with the record date being 15th day of the month prior to the payment date (NOTE: the ex-dividend date is one business day prior to the record date). Dividends paid by this preferred security are eligible for the preferential income tax rate of 15% to a maximum of 20% depending on the holder's tax bracket (and under IRS specified holding restrictions) and are also eligible for the dividends received deduction for corporate holders (see page S-29 of the prospectus for further information).

    Upon the occurrence of a change of control the company will have the option within 120 days to redeem the preferred shares at $25 per share plus accrued and unpaid dividends. If the company has exercised their redemption right, the holders will NOT have the following conversion right. Upon the occurrence of a change of control, and the company has NOT provided notice that they intend to redeem the preferred shares, the holder will have the right to convert the preferred shares into common shares under certain circumstances (see the prospectus for details).

    This security was not rated by Moody’s or S&P at the time of its IPO. In regard to the payment of dividends and upon liquidation, the preferred shares rank junior to the company's senior debt, equally with other preferreds of the company, and senior to the common shares of the company. See the IPO prospectus for further information on the preferred stock by clicking on the ‘Link to IPO Prospectus’ provided below.

    Stock
    Exchange
    Cpn Rate
    Ann Amt
    LiqPref
    CallPrice
    Call Date
    Matur Date
    Moodys/S&P
    Dated
    Distribution Dates 15%
    Tax Rate
    NCM
    Chart
    9.38%
    $2.34
    $25.00
    $25.00
    12/15/2022
    None
    NF NF
    6/15/2025
    Suspended!
    Last day of the month
    Click for MW ExDiv Date
    Click for Yahoo ExDiv Date
    YES

    Go to Parent Company's Record (FBIO)

    Notes:  June 17, 2020 -- the stockholders of the Company voted at the 2020 Annual Meeting to approve amendment to the Company’s Amended and Restated Certificate of Incorporation to (i) increase the number of shares of common stock authorized for issuance by 50,000,000 shares, bringing the total number of authorized shares of common stock to 150,000,000 shares (the “Authorized Shares Amendment”) and (ii) increase the frequency of the dividend payments on the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock from quarterly to monthly (the “Perpetual Preferred Dividend Frequency Amendment”).

    IPO - 11/6/2017 - 1.00 Million Shares @ $25.00 /share.    Link to IPO Prospectus
    Market Value $ Million
    Click for current FBIOP price quote from the NASDAQ

    Company's Online Information Links
    HOME PAGE:     https://www.fortressbiotech.com/
    Company's Investor Relations Information Go to Investor Relations Information
    Company's Online News Releases Go to News Releases
    Online Company Profile Go to Online Profile

    Company's Online SEC EDGAR Filings
    Company's SEC EDGAR Filings Go to SEC Filings

    Company's Email Address Links
    Inv Rel Email Address ir@fortressbiotech.com
    General Email Address info@fortressbiotech.com
    Email Contact Form on Website Go to Email Form

    Address and Phone Numbers
    Address:   1111 Kane Concourse Suite 301, Bay Harbor Islands, FL 33154
    Main Phone Number 781-652-4500
    Fax Number Not Available
    Investor Relations   Jaclyn Jaffe 781-652-4500
    CEO - Lindsay Rosenwald CFO - David Jin


    Find a problem? Please use our Feedback Page or Email us.
    Have you filled out our Guestbook? If not, please do.




    QuantumOnline.com
    Copyright © 1997 - 2026 QuantumOnline.com. All rights reserved.
    Web page design latest update: 2/10/2026
    Web page financial information is most recent information available and more recent than last web page design date.